Long-term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy Journal Article


Authors: Teo, M. Y.; Guercio, B. J.; Arora, A.; Hao, X.; Regazzi, A. M.; Donahue, T.; Herr, H. W.; Goh, A. C.; Cha, E. K.; Pietzak, E.; Donat, S. M.; Dalbagni, G.; Bochner, B. H.; Olgac, S.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Gopalan, A.; Fine, S. W.; Tickoo, S. K.; Reuter, V. E.; Weigelt, B.; Schultheis, A. M.; Funt, S. A.; Bajorin, D. F.; Solit, D. B.; Iyer, G.; Ostrovnaya, I.; Rosenberg, J. E.; Al-Ahmadie, H.
Article Title: Long-term outcomes of local and metastatic small cell carcinoma of the urinary bladder and genomic analysis of patients treated with neoadjuvant chemotherapy
Abstract: Introduction: Small cell carcinoma of the bladder (SCCB) is a rare variant of bladder cancer with poor outcomes. We evaluated long-term outcomes of nonmetastatic (M0) and metastatic (M1) SCCB and correlated pathologic response with genomic alterations of patients treated with neoadjuvant chemotherapy (NAC). Patients and Methods: Clinical history and pathology samples from SCCB patients diagnosed at our institution were reviewed. Results: One hundred and ninety-nine SCCB patients were identified. (M0: 147 [74%]; M1: 52 [26%]). Among M0 patients, 108 underwent radical cystectomy (RC) (NAC: 71; RC only: 23; adjuvant chemotherapy: 14); 14 received chemoradiotherapy; the rest received chemotherapy alone or no cancer-directed therapy. RC-only patients had a median follow-up of 9.1 years, and median disease-free survival (DFS) and overall survival (OS) were 1.1 and 1.2 years, respectively. NAC patients had pathologic response (<pT2pN0) and pathologic complete response (pT0pN0) rates of 48% and 38%, respectively, with median follow-up of 7.2 years, and median DFS and OS of 5.6 and 14.5 years, respectively. NAC responders (<ypT2N0) had superior median DFS (14.5 vs. 0.6 years, hazard ratio [HR] 0.24, P< .001) and OS (14.5 vs. 2.5 years, HR 0.31, P = .002). DFS rates for responders and nonresponders were 76% and 27% at 5 years, and 71% and 23% at 10 years, respectively. Local and central nervous system recurrences were infrequent. Median progression-free survival (PFS) and OS for M1 disease were 6.9 and 10.3 months, respectively. Genomic profiling was performed on 47 NAC patients. Loss of ERCC2 function was significantly enriched among those with pathologic complete response to NAC (mutations present in 50% of pathologic complete responders vs. 15% nonresponders, P = .045). Conclusion: M0 SCCB is chemo-sensitive and patients have excellent long-term survival following response to NAC. Patients with M1 disease have poor survival despite systemic therapy. Loss-of-function mutations of ERCC2 were associated with pathologic complete response to NAC. © 2022 Elsevier Inc.
Keywords: bladder cancer; radical cystectomy; urothelial carcinoma; neuroendocrine carcinoma; small cell bladder cancer
Journal Title: Clinical Genitourinary Cancer
Volume: 20
Issue: 5
ISSN: 1558-7673
Publisher: Elsevier Inc.  
Date Published: 2022-10-01
Start Page: 431
End Page: 441
Language: English
DOI: 10.1016/j.clgc.2022.05.005
PUBMED: 35676169
PROVIDER: scopus
PMCID: PMC9809986
DOI/URL:
Notes: Article -- Export Date: 3 October 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dean Bajorin
    663 Bajorin
  2. Guido Dalbagni
    327 Dalbagni
  3. Sherri M Donat
    176 Donat
  4. David Solit
    783 Solit
  5. Satish K Tickoo
    487 Tickoo
  6. Anuradha Gopalan
    421 Gopalan
  7. Gopakumar Vasudeva Iyer
    358 Iyer
  8. Yingbei Chen
    402 Chen
  9. Bernard Bochner
    473 Bochner
  10. Samson W Fine
    468 Fine
  11. Victor Reuter
    1234 Reuter
  12. Harry W Herr
    598 Herr
  13. Ashley Regazzi
    93 Regazzi
  14. Jonathan Eric Rosenberg
    524 Rosenberg
  15. Arshi Arora
    36 Arora
  16. Timothy Francis Donahue
    75 Donahue
  17. Britta Weigelt
    646 Weigelt
  18. Eugene K. Cha
    102 Cha
  19. Samuel Aaron Funt
    143 Funt
  20. Min Yuen   Teo
    106 Teo
  21. Eugene J Pietzak
    120 Pietzak
  22. Alvin Chun chin Goh
    77 Goh
  23. Brendan John Guercio
    16 Guercio